- Title
- Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
- Creator
- Johansson, Harriet; Gray, Kathryn P.; Colleoni, Marco; Rabaglio, Manuela; Price, Karen N.; Coates, Alan S.; Gelber, Richard D.; Goldhirsch, Aron; Kammler, Roswitha; Bonanni, Bernardo; Walley, Barbara A.; TEXT principal investigators,; Pagani, Olivia; Chirgwin, Jaqueline; Francis, Prudence; Regan, Meredith M.; Viale, Giuseppe; Aristarco, Valentina; Macis, Debora; Puccio, Antonella; Roux, Susanne; Maibach, Rudolf
- Relation
- NHMRC.351161 http://purl.org/au-research/grants/nhmrc/351161
- Relation
- Breast Cancer Research Vol. 18, no. 110
- Publisher Link
- http://dx.doi.org/10.1186/s13058-016-0771-8
- Publisher
- BioMed Central
- Resource Type
- journal article
- Date
- 2016
- Description
- Background: Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have been associated with breast cancer risk, endocrine therapy response and side effects, mainly in postmenopausal women with early breast cancer. This analysis aimed to assess the association of selected germline CYP19A1 and ESR1 SNPs with early-onset hot flashes, sweating and musculoskeletal symptoms in premenopausal patients enrolled in the Tamoxifen and Exemestane Trial (TEXT). Methods: Blood was collected from consenting premenopausal women with hormone-responsive early breast cancer, randomly assigned to 5-years of tamoxifen plus ovarian suppression (OFS) or exemestane plus OFS. DNA was extracted with QIAamp kits and genotyped for two CYP19A1 (rs4646 and rs10046) and three ESR1 (rs2077647, rs2234693 and rs9340799) SNPs by a real-time pyrosequencing technique. Adverse events (AEs) were recorded at baseline and 3-monthly during the first year. Associations of the genotype variants with grade ≥2 early-onset targeted AEs of hot flashes/sweating or musculoskeletal events were assessed using logistic regression models. Results: There were 2660 premenopausal patients with breast cancer in the intention-to-treat population of TEXT, and 1967 (74 %) are included in this translational study. The CYP19A1 rs10046 variant T/T, represented in 23 % of women, was associated with a reduced incidence of grade ≥2 hot flashes/sweating (univariate odds ratio (OR) = 0.78; 95 % CI 0.63–0.97; P = 0.03), more strongly in patients assigned exemestane + OFS (TT vs CT/CC: OR = 0.65, 95 % CI = 0.48–0.89) than assigned tamoxifen + OFS (OR = 0.94, 95 % CI = 0.69–1.27, interaction P = 0.03). No association with any of the CYP19A1/ESR1 genotypes and musculoskeletal AEs was found. Conclusion: The CYP19A1 rs10046 variant T/T favors lower incidence of hot flashes/sweating under exemestane + OFS treatment, suggesting endocrine-mediated effects. Based on findings from others, this SNP may potentially enhance treatment adherence and treatment efficacy. We plan to evaluate the clinical impact of this polymorphism during time, pending sufficient median follow up.
- Subject
- side effects; aromatase inhibitors; tamoxifen; ovarian suppression; breast cancer; CYP19A1; ESR1
- Identifier
- http://hdl.handle.net/1959.13/1339372
- Identifier
- uon:28241
- Identifier
- ISSN:1465-542X
- Rights
- © The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. N354491
- Language
- eng
- Full Text
- Reviewed
- Hits: 37075
- Visitors: 23564
- Downloads: 480
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 475 KB | Adobe Acrobat PDF | View Details Download |